TITLE

Aerosolised ribavirin in patients with advanced cryptogenic fibrosing alveolitis: a pilot study

AUTHOR(S)
Agustí, C; Xaubet, A; Ballester, E; Alarcón, A; Picado, C
PUB. DATE
January 1993
SOURCE
Thorax;Jan1993, Vol. 48 Issue 1, p68
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66098226

 

Related Articles

  • Cryptogenic Fibrosing Alveolitis Predating Ulcerative Colitis. De Llano, Luis A. Pérez; Lancho, Angel; Del Cerro, J. L. Soilán; López-Rosés, Leopoldo // American Journal of Gastroenterology;Apr1996, Vol. 91 Issue 4, p822 

    Presents a letter to the editor on cryptogenic fibrosing alveolitis predating ulcerative colitis.

  • Minerva.  // BMJ: British Medical Journal (International Edition);04/11/98, Vol. 316 Issue 7138, p1178 

    Presents information on developments in medicine. Information on injuries from snowmobiles; Account on an approach for treating metastatic breast cancer; Survival period of patients with cryptogenic fibrosing alveolitis.

  • What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. Scott, Jonathan; Johnston, Ian; Britton, John // BMJ: British Medical Journal (International Edition);11/3/90, Vol. 301 Issue 6759, p1015 

    Examines the etiology of cryptogenic fibrosing alveolitis in Nottingham, England. Role of the occupational and domestic exposure to dust for the development of the disease; Survival of patients after a month of diagnosed; Evaluation of the restrictive pulmonary function test for the investigation.

  • Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Bernstein, R.M.; Morgan, S.H.; Chapman, J.; Bunn, C.C.; Mathews, M.B.; Turner-Warick, M.; Hughes, G.R.V. // British Medical Journal (Clinical Research Edition);7/21/1984, Vol. 289 Issue 6438, p151 

    Discusses the function of anti-jo-1 antibody in patients with myositis and cryptogenic fibrosing alveolitis in Great Britain. Definition of myositis; Identification of the antibody by counterimmunoelectrophoresis; Usage of cytotoxic drugs.

  • Fibrosing alveolitis in patients with RA. Saravanan, V.; Kelly, C. A. // Thorax;Apr2002, Vol. 57 Issue 4, p375 

    Presents a letter to the editor about fibrosing alveolitis in patients with rheumatoid arthritis.

  • SCIENTIFIC FRONTIERS IN LUNG DISEASE.  // Thorax;Dec2001 Supp, Vol. 56, piii41 

    This article presents various studies related to scientific frontiers in lung disease. The immune pathology of sarcoidosis is characterized by an exaggerated CD4 T cell response to an undefined antigens. Spontaneous remission occurs in the majority of subjects, but 30% of patients develon...

  • Pulmonary Fibrosis.  // Current Medical Literature: Respiratory Medicine;2010, Vol. 24 Issue 1, p23 

    The article reviews several studies on pulmonary fibrosis. It cites an investigation on the effect of bosentan in patients with idiopathic pulmonary fibrosis (IPF) in the Bosentan Use in Interstitial Lung Disease-1 (BUILD-1) trial which note that endothelin antagonists do not have any proven...

  • Autoantibodies in cryptogenic fibrosing alveolitis. Singh, Suveer; Du Bois, Ron // Respiratory Research;2001, Vol. 2, p61 

    The pathogenesis of cryptogenic fibrosing alveolitis (CFA) involves injury, an immune/inflammatory response and fibrosis. The cause of the injury is unknown, but the identification of serum autoantibodies makes an autoimmune aetiology attractive. The core study on which this commentary is based...

  • A survey of nocturnal hypoxaemia and health related quality of life in patients with cryptogenic fibrosing alveolitis. Clark, M.; Cooper, B.; Singh, S.; Cooper, M.; Carr, A.; Hubbard, R. // Thorax;Jun2001, Vol. 56 Issue 6, p482 

    Background: A survey of overnight oximetry was conducted to estimate the prevalence of nocturnal hypoxaemia in patients with cryptogenic fibrosing alveolitis and to establish whether nocturnal hypoxaemia is related to quality of life. Methods: All patients with...

  • Rising mortality from cryptogenic fibrosing alveolitis. Johnston, Ian; Britton, John; Kinnear, William; Logan, Richard // BMJ: British Medical Journal (International Edition);11/3/90, Vol. 301 Issue 6759, p1017 

    Examines the mortality rate caused by cryptogenic fibrosing alveolitis in Great Britain. Identification of factors important in the etiology of the disease; Assessment of the validity of death certification of the disease; Treatment and management of the disease.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics